30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Biomet

(for period ended 11/30/14)

$844MM, +4% (U.S. $512MM, +4%; Europe $206MM, +1%; Other International $125MM, +10%) (Without Dental, $776MM, +3%)

  • Hips $168.0MM, +3% (U.S. flat)
  • Knees $264.3MM, +2% (U.S. -0.4%)
  • Sports Med/Extremities/Trauma (S.E.T.) $160.6MM, +2% (U.S. +3%)
  • Spine, Bone Healing & Microfixation $124.5MM, +20% (U.S. +18%)
  • Dental $67.6MM, -2%
  • Cement, Biologics & Other $58.6MM, +4% (U.S. +7%)

 

Recon

  • Growth supported by Taperloc Complete Microplasty Hip, G7 Multi-Bearing Acetabular System and Arcos Modular Femoral Revision in hips, Vanguard Knee and Oxford Partial Knee in Europe
  • Partially offset by modest salesforce attrition
  • Launched G7 Bispherical shell in Europe
  • Launched XPA bi-cruciate preserving system
  • ~300 healthcare professionals trained on Oxford, 120 additional surgeons trained on XPA
  • 1,650 XP knees implanted to date in 9 countries
  • Direct-to-consumer Vanguard XP campaign launched in spot markets, more scheduled for 3Q

 

S.E.T.

  • 28th consecutive quarter of double-digit growth, supported by JuggerKnotless all-suture Labral Repair and anatomic, reverse and fracture Comprehensive Shoulder, as well as Signature Patient Specific Glenoid Guides (shipped >1,200 worldwide) and AFFIXUS hip nail
  • 3Q launches include Juggerknotless in Europe, Signature guides and ePAK Single-Use Delivery system in Japan

 

Spine/Bone Healing/Microfixation

  • Buoyed by increased demand for spine hardware systems and spine-related osteobiologics, cross-selling synergies from Lanx acquisition
  • Completed 1st procedure with Timberline MPF hyperlordotic system

 

Cement, Biologics & Other

  • Biologics grew at double-digits, supported by strong sales of Cellentra, Cerament, BioCUE aspiration system
  • Stage 1 Shoulder Spacer Molds launched in Australia, will launch in Canada in 3Q